419 related articles for article (PubMed ID: 30050094)
1. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.
Cabel L; Proudhon C; Romano E; Girard N; Lantz O; Stern MH; Pierga JY; Bidard FC
Nat Rev Clin Oncol; 2018 Oct; 15(10):639-650. PubMed ID: 30050094
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
3. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
[No Abstract] [Full Text] [Related]
4. Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy.
Failing JJ; Dudek OA; Marin Acevedo JA; Chirila RM; Dong H; Markovic SN; Dronca RS
Future Oncol; 2019 Aug; 15(22):2645-2656. PubMed ID: 31298573
[TBL] [Abstract][Full Text] [Related]
5. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
[TBL] [Abstract][Full Text] [Related]
6. Utilizing circulating tumour DNA in radiation oncology.
Rostami A; Bratman SV
Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
[TBL] [Abstract][Full Text] [Related]
7. Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions.
Liu Z; Han Y; Dang Q; Xu H; Zhang Y; Duo M; Lv J; Li H; Kong Y; Han X
Int Immunopharmacol; 2022 Oct; 111():109173. PubMed ID: 35998502
[TBL] [Abstract][Full Text] [Related]
8. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
Iijima Y; Hirotsu Y; Amemiya K; Ooka Y; Mochizuki H; Oyama T; Nakagomi T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Goto T; Miyashita Y; Omata M
Eur J Cancer; 2017 Nov; 86():349-357. PubMed ID: 29078173
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.
Cabel L; Riva F; Servois V; Livartowski A; Daniel C; Rampanou A; Lantz O; Romano E; Milder M; Buecher B; Piperno-Neumann S; Bernard V; Baulande S; Bieche I; Pierga JY; Proudhon C; Bidard FC
Ann Oncol; 2017 Aug; 28(8):1996-2001. PubMed ID: 28459943
[TBL] [Abstract][Full Text] [Related]
10. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
11. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.
Khagi Y; Goodman AM; Daniels GA; Patel SP; Sacco AG; Randall JM; Bazhenova LA; Kurzrock R
Clin Cancer Res; 2017 Oct; 23(19):5729-5736. PubMed ID: 28972084
[No Abstract] [Full Text] [Related]
12. Current and Future Clinical Applications of ctDNA in Immuno-Oncology.
Stadler JC; Belloum Y; Deitert B; Sementsov M; Heidrich I; Gebhardt C; Keller L; Pantel K
Cancer Res; 2022 Feb; 82(3):349-358. PubMed ID: 34815256
[TBL] [Abstract][Full Text] [Related]
13. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
Teng F; Meng X; Kong L; Yu J
Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
[TBL] [Abstract][Full Text] [Related]
14. Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications.
Huang C; Liu S; Tong X; Fan H
Cancer Chemother Pharmacol; 2018 Aug; 82(2):171-183. PubMed ID: 29948020
[TBL] [Abstract][Full Text] [Related]
15. Pseudoprogression and hyperprogression after checkpoint blockade.
Wang Q; Gao J; Wu X
Int Immunopharmacol; 2018 May; 58():125-135. PubMed ID: 29579717
[TBL] [Abstract][Full Text] [Related]
16. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
Abbosh C; Birkbak NJ; Swanton C
Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour DNA for clinicians: current and future clinical applications.
Thompson MK; Gale D; Brenton JD
Clin Radiol; 2021 Oct; 76(10):737-747. PubMed ID: 34389159
[TBL] [Abstract][Full Text] [Related]
18. Circulating-tumor DNA as an early detection and diagnostic tool.
Butler TM; Spellman PT; Gray J
Curr Opin Genet Dev; 2017 Feb; 42():14-21. PubMed ID: 28126649
[TBL] [Abstract][Full Text] [Related]
19. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
Barlebo Ahlborn L; Østrup O
APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
[TBL] [Abstract][Full Text] [Related]
20. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]